Literature DB >> 17329303

Risperidone-to-methylphenidate switch reaction in children: three cases.

Osman Sabuncuoglu1.   

Abstract

As atypical antipsychotics are increasingly used in the treatment of childhood behavioural disorders either as monotherapy or in combination with other medications, there is a need to know more about their safety, in particular during switching to and from methylphenidate treatment, as antipsychotics and methylphenidate have opposing effects on dopaminergic neurotransmission. This report is about three cases of children who developed severe adverse reactions during switching from risperidone to methylphenidate. The first patient was a 6-year-old boy, diagnosed with attention deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment. The second patient was a girl of 6, already on risperidone for ADHD and borderline intellectual functioning when referred. She displayed severe hyperactivity, agitation and irritability upon switching to methylphenidate medication. The third patient was a 15-year-old female adolescent with a similar clinical course as the previous patients. In all the cases described here, it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug-free interval. Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate. Thus, a drug-free interval is recommended in order to prevent adverse reactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329303     DOI: 10.1177/0269881107069466

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

1.  The dopamine dilemma: using stimulants and antipsychotics concurrently.

Authors:  Jason Yanofski
Journal:  Psychiatry (Edgmont)       Date:  2010-06

2.  Onset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.

Authors:  Presenters Ornella Potter; Nadyah John; Discussant Barbara J Coffey
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-10       Impact factor: 2.576

Review 3.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09

4.  Dystonia in an adolescent on risperidone following the discontinuation of methylphenidate: a case report.

Authors:  Gulen Guler; Veli Yildirim; Meryem Ozlem Kutuk; Fevziye Toros
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

5.  Dystonia with MPH/Risperidone Combined Therapy for ADHD.

Authors:  J Gordon Millichap; Michelle M Yee
Journal:  Pediatr Neurol Briefs       Date:  2016-01

Review 6.  Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review.

Authors:  Noa Tsujii; Masahide Usami; Noriyuki Naya; Toshinaga Tsuji; Hirokazu Mishima; Junko Horie; Masakazu Fujiwara; Junzo Iida
Journal:  Neurol Ther       Date:  2021-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.